Search - tctmd.com

Displaying 321 - 340 of 1320

Sort: Relevancy | Date

News Conference News TCT 2018

SOLVE-TAVI: TAVR Equally Safe With Balloon-, Self-Expanding Valves and General, Local Anesthesia

Yael L. Maxwell

September 23, 2018

Presentation TCT 2018

All-Cause Mortality and Interpretation of Secondary Endpoints: The VEST and ODYSSEY Examples

Presenter: E. Magnus Ohman, Stuart J. Pocock

September 23, 2018

Presentation TCT 2018

What Are the Lasting Clinical Implications Of the ORBITA Trial?

Presenter: Anibal A. Damonte, Diego D Grinfeld, Alfredo E. Rodriguez, John A. Ambrose

September 23, 2018

Presentation TCT 2018

Patient Perspectives on Sham-Controlled Trials

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Debbe McCall

September 23, 2018

News Conference News TCT 2018

Denervation Has Possible Benefit for Pulmonary Hypertension Related to Left Heart Failure

Todd Neale

September 23, 2018

News Daily News TCT 2018

High Mortality but Durable Results With Valve-in-Valve TAVR

Michael O'Riordan

September 23, 2018

Presentation TCT 2018

FDA Perspectives on Sham-Controlled Trials

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Hiren Mistry

September 23, 2018

Presentation TCT 2018

ISCHEMIA Trial in the Spotlight: Why All the Fuss Over the Change in the Primary Endpoint?

Presenter: E. Magnus Ohman, Stuart J. Pocock, David J. Maron

September 23, 2018

Presentation TCT 2018

Sham Controls in Renal Denervation Studies: Need to Have vs Nice to Have?

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, David E. Kandzari

September 23, 2018

Presentation TCT 2018

Composite Endpoints: When Are They Valid and When Should They Be Discarded

Presenter: E. Magnus Ohman, Stuart J. Pocock, Sanjay Kaul

September 23, 2018

Presentation TCT 2018

ORBITA One Year Later: What Would I Do Differently, If Anything?

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Rasha Al-Lamee

September 23, 2018

Presentation TCT 2018

TRIVALVE: Evaluation of Edge-to-Edge Valve Repair for Symptomatic Tricuspid Regurgitation

Presenter: Valentin Fuster, Jörg Hausleiter

September 23, 2018

Presentation TCT 2018

Case #4: Clinically Significant TAVR Leaflet Thrombosis

Presenter: Samir R. Kapadia, Bernard Prendergast, Eric Eeckhout, Ganesh Manoharan, John C. Messenger, Bernhard Reimers, Paul Sorajja, Eric Vang

September 23, 2018

Presentation TCT 2018

Prosthesis-Patient Mismatch: Incidence, Predictors, and Outcome of Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Replacement

Presenter: Valentin Fuster, Howard C. Herrmann

September 23, 2018

Presentation TCT 2018

PARTNER VALVE-IN-VALVE: Late Follow-up After Treatment of Failing Surgical Aortic Bioprosthetic Valves With a Balloon-Expandable Transcatheter Heart Valve

Presenter: John G. Webb

September 23, 2018

Presentation TCT 2018

PADN-5: A Randomized Trial of Pulmonary Artery Denervation in Patients With Combined Pre- and Postcapillary Pulmonary Hypertension

Presenter: Valentin Fuster, Shao-Liang Chen

September 23, 2018

Presentation TCT 2018

Clinical Trial Considerations for Transcatheter TR Therapies

Presenter: Ori Ben-Yehuda

September 23, 2018

Presentation TCT 2018

NAVIGATE Transcatheter Tricuspid Valve Replacement Early Findings Technology and Clinical Updates

Presenter: Rebecca T. Hahn

September 23, 2018

Presentation TCT 2018

Evolution of Caval Valves (CAVI) Last Resort TR Patients Technology and Clinical Updates

Presenter: Alexander Lauten

September 23, 2018

Presentation TCT 2018

The FORMA Spacer A Versatile Tool Technology and Clinical Updates

Presenter: Gidon Yehuda Perlman

September 23, 2018

Advertisement

SOLVE-TAVI: TAVR Equally Safe With Balloon-, Self-Expanding Valves and General, Local Anesthesia

All-Cause Mortality and Interpretation of Secondary Endpoints: The VEST and ODYSSEY Examples

What Are the Lasting Clinical Implications Of the ORBITA Trial?

Patient Perspectives on Sham-Controlled Trials

Denervation Has Possible Benefit for Pulmonary Hypertension Related to Left Heart Failure

High Mortality but Durable Results With Valve-in-Valve TAVR

FDA Perspectives on Sham-Controlled Trials

ISCHEMIA Trial in the Spotlight: Why All the Fuss Over the Change in the Primary Endpoint?

Sham Controls in Renal Denervation Studies: Need to Have vs Nice to Have?

Composite Endpoints: When Are They Valid and When Should They Be Discarded

ORBITA One Year Later: What Would I Do Differently, If Anything?

TRIVALVE: Evaluation of Edge-to-Edge Valve Repair for Symptomatic Tricuspid Regurgitation

Case #4: Clinically Significant TAVR Leaflet Thrombosis

Prosthesis-Patient Mismatch: Incidence, Predictors, and Outcome of Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Replacement

PARTNER VALVE-IN-VALVE: Late Follow-up After Treatment of Failing Surgical Aortic Bioprosthetic Valves With a Balloon-Expandable Transcatheter Heart Valve

PADN-5: A Randomized Trial of Pulmonary Artery Denervation in Patients With Combined Pre- and Postcapillary Pulmonary Hypertension

Clinical Trial Considerations for Transcatheter TR Therapies

NAVIGATE Transcatheter Tricuspid Valve Replacement Early Findings Technology and Clinical Updates

Evolution of Caval Valves (CAVI) Last Resort TR Patients Technology and Clinical Updates

The FORMA Spacer A Versatile Tool Technology and Clinical Updates

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content